Association of miR-338-3p with survival outcomes in gastric cancer patients who received peri-operative blood transfusion.

IF 2.8 3区医学 Q2 ONCOLOGY Clinical & Translational Oncology Pub Date : 2025-02-01 Epub Date: 2024-08-04 DOI:10.1007/s12094-024-03628-9

Haiyan Shi, Yunfei Feng, Shaozhan Yuan, Juchuan Chai

{"title":"Association of miR-338-3p with survival outcomes in gastric cancer patients who received peri-operative blood transfusion.","authors":"Haiyan Shi, Yunfei Feng, Shaozhan Yuan, Juchuan Chai","doi":"10.1007/s12094-024-03628-9","DOIUrl":null,"url":null,"abstract":"Background: Perioperative blood transfusion (BT) is frequent in the treatment of gastric cancer (GC), but its effects on the prognosis of GC remains controversial. In this study, we aimed to further confirm the relationship of perioperative BT with GC overall survival and to evaluate the predictive value of microRNA-338-3p (miR-338-3p) for the prognosis of GC patients who received perioperative BT.Methods: Clinical data and serum samples were collected and analyzed from 246 patients with GC. Five-year follow-up survival information was assessed by Kaplan-Meier survival analysis. miR-338-3p relative expression was assessed by RT-qPCR, and its relationship with the prognosis of GC patients, who received perioperative BT, was evaluated using Kaplan-Meier curves and Cox regression analysis.Results: GC patients received perioperative BT had poor 5 year survival than those without BT. In patients received BT, miR-338-3p expression was higher in survival cases than died population and high miR-338-3p was independently associated with better overall survival prognosis.Conclusion: Perioperative BT is related with poor prognosis in GC patients and miR-338-3p may be a prognostic biomarker for GC patients received perioperative BT. BT in perioperative GC patients should be cautious, especially for those with low levels of miR-338-3p.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"604-611"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03628-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Perioperative blood transfusion (BT) is frequent in the treatment of gastric cancer (GC), but its effects on the prognosis of GC remains controversial. In this study, we aimed to further confirm the relationship of perioperative BT with GC overall survival and to evaluate the predictive value of microRNA-338-3p (miR-338-3p) for the prognosis of GC patients who received perioperative BT.

Methods: Clinical data and serum samples were collected and analyzed from 246 patients with GC. Five-year follow-up survival information was assessed by Kaplan-Meier survival analysis. miR-338-3p relative expression was assessed by RT-qPCR, and its relationship with the prognosis of GC patients, who received perioperative BT, was evaluated using Kaplan-Meier curves and Cox regression analysis.

Results: GC patients received perioperative BT had poor 5 year survival than those without BT. In patients received BT, miR-338-3p expression was higher in survival cases than died population and high miR-338-3p was independently associated with better overall survival prognosis.

Conclusion: Perioperative BT is related with poor prognosis in GC patients and miR-338-3p may be a prognostic biomarker for GC patients received perioperative BT. BT in perioperative GC patients should be cautious, especially for those with low levels of miR-338-3p.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

miR-338-3p与接受围手术期输血的胃癌患者生存预后的关系

背景：围手术期输血（BT）在胃癌（GC）治疗中很常见，但其对GC预后的影响仍存在争议。本研究旨在进一步证实围手术期输血与胃癌总生存率的关系，并评估微RNA-338-3p（miR-338-3p）对接受围手术期输血的胃癌患者预后的预测价值：收集并分析了246名GC患者的临床数据和血清样本。用 RT-qPCR 评估 miR-338-3p 的相对表达，并用 Kaplan-Meier 曲线和 Cox 回归分析评估 miR-338-3p 与接受围手术期 BT 的 GC 患者预后的关系：结果：与未接受 BT 的患者相比，接受围手术期 BT 的 GC 患者的 5 年生存率较低。在接受 BT 的患者中，存活病例的 miR-338-3p 表达高于死亡人群，高 miR-338-3p 与更好的总生存预后独立相关：结论：围手术期 BT 与 GC 患者的不良预后有关，而 miR-338-3p 可能是接受围手术期 BT 的 GC 患者的预后生物标志物。对围术期 GC 患者进行 BT 应持谨慎态度，尤其是那些 miR-338-3p 水平较低的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.